At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 107 enrolled
Drug / intervention
SHR-1701+Paclitaxel+carboplatin +1 moredrug
Likely dose
SHR-1701+Paclitaxel+carboplatin 30mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter Phase II Clinical Trial of SHR-1701 With or Without Chemotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating SHR-1701+Paclitaxel+carboplatin and SHR-1701 for Non-Small-Cell Lung Cancer. Targeting 107 participants across 1 site.
Detailed Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small-Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionJul 2023
Study CompletionMar 2025
TodayJul 2026
First PostedOct 8, 2020
Enrollment StartNov 10, 2020
Primary CompletionJul 15, 2023
Study CompletionMar 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 5.7 years ago
Interventions
SHR-1701+Paclitaxel+carboplatindrug
Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
SHR-1701drug
Drug: SHR-1701 30mg/kg